Ground-breaking trial offers new hope for children with brain cancer
Maria and family at PCH with Paediatric Oncologist Dr Santosh Valvi
Eleven-year-old Maria has become the first child in Australia to join an international clinical trial at Perth Children's Hospital (PCH) testing a targeted treatment for an aggressive form of brain cancer.
After experiencing persistent headaches last year, Maria and her family were surprised to learn she had a high-grade glioma, a fast-growing and difficult-to-treat brain tumour.
Following radiation therapy, Maria was enrolled in the CONNECT-TarGeT Arm A clinical trial, led at PCH by Paediatric Oncologist Dr Santosh Valvi.
The study is investigating a combination of two oral medications designed to target specific genetic changes within a patient's tumour.
The trial represents a significant step forward for children and families in Western Australia, providing access to cutting-edge research closer to home.
Dr Valvi said the treatment aimed to personalise care for children whose tumours contained specific genetic characteristics.
"The trial is using two agents which are targeting the specific genetic change in the tumour," Dr Valvi said.
"Previously, our patients would need to travel to Sydney or Melbourne to participate in similar clinical trials."
The international study offers a precision medicine approach, matching treatment to the genetic profile of a child's cancer.
Researchers hope the targeted oral medications will help slow tumour growth and improve quality of life for children.
For Maria's family, access to the trial has brought renewed hope during an incredibly challenging time.
While there is currently no cure for high-grade glioma, Maria's family remains optimistic about the opportunity the trial provides.
The family is also encouraging other parents to seek medical advice if their child experiences ongoing or unexplained symptoms, including persistent headaches.
Dr Valvi said expanding access to clinical trials in Western Australia was helping ensure local children could benefit from the latest advances in paediatric cancer care without the added burden of interstate travel.
The CONNECT-TarGeT Arm A trial marks an important milestone for paediatric cancer research in Australia and signals the growing availability of precision medicine approaches at PCH.